Synthesis, purification, and in vitro stability of 211At- and 125I-labeled amidobisphosphonates

Nuclear Medicine and Biology

Volumn 26, Issue 4, 1999, Pages 397-403

  Murud, Kristin M ^a   Larsen, Roy H ^a   Hoff, Per ^a   Zalutsky, Michael R ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Astatine 211; Bisphosphonates; Bone palliation; Radiotherapy

Indexed keywords

ASTATINE 211; BENZOIC ACID DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; IODINE 125; PAMIDRONIC ACID; PYRIDINE DERIVATIVE; SUCCINIMIDE DERIVATIVE;

ARTICLE; BONE TUMOR; DRUG PURIFICATION; DRUG STABILITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOTOPE LABELING; LIPOPHILICITY; MOUSE; NONHUMAN; RADIOIODINATION; RADIOISOTOPE THERAPY;

ANIMALS; ASTATINE; BONE AND BONES; DIPHOSPHONATES; DRUG STABILITY; HUMANS; IODINE RADIOISOTOPES; ISOTOPE LABELING; MICE; SOLUBILITY;

EID: 0032981887     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(98)00119-X     Document Type: Article

References (30)

1. Atkins H.L. Overview of nuclides for bone palliation. Appl. Radiat. Isot. 49:1998;277-283.
2. Atkins H.L., Mausner L.F., Srivastava S.C., Meinken G.E., Straub R.F., Cabahug C.J., Weber D.A., Wong C.T., Sacker D.F., Madajewics S. Biodistribution of Sn-117m(4+)DTPA for palliative theraphy of painful osseous metastases. Radiology. 186:1993;279-283.
3. Ettre L.S. The new IUPAC nomenclature for chromatography. LC-GC. 11:1993;502-506.
4. Deutsch E., Libson K., Vanderheyden J.-L., Ketering A., Maxon H.R. The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine. Nucl. Med. Biol. 13:1986;465-477.
5. Fleisch H. Bisphosphonates in Bone Disease. From the Laboratory to the Patient. 2nd edn. 1995;The Parthenon Publishing Group, New York.
6. Foulon C.F., Alston K.L., Zalutsky M.R. Synthesis and preliminary biological evaluation of (3-iodobenzoyl)norbiotinamide and ([5-iodo-3-pyridine]carbonyl)norbiotinamide Two radioiodinated biotin conjugated with improved stability . Bioconjugate Chem. 8:1997;179-186.
7. Foulon C.F., Alston K.L., Zalutsky M.R. Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy. Nucl. Med. Biol. 25:1998;81-88.
8. 211At]astatoaniline . Nucl. Med. Biol. 24:1997;135-143.
9. Frey K.A., Wieland D.M., Brown L.E., Rogers W.L., Agranoff B.W. Development of tomographic myelin scan. Ann. Neurol. 10:1981;214-221.
10. Garg S., Garg P.K., Zalutsky M.R. N-Succinimidyl 5-(trialkylstannyl)-3- pyridinecarboxylates A new class of reagents for protein radioiodination . Bioconjugate Chem. 2:1991;50-56.
11. 153Sm Radiotherapeutic bone agents. Nucl. Med. Biol. 13:1986;479-482.
12. 188Re, and a study of its stability. Appl. Radiat. Isot. 49:1998;351-356.
13. Hassfjell S.P., Bruland O.S., Hoff P. 211-Bi-DOTMP-An alpha particle emitting bone seeking agent for targeted radiotherapy. Nucl. Med. Biol. 24:1997;231-237.
14. Hosain F., Spencer R.P., Couthon H.M., Sturtz G.L. Targeted delivery of antineoplastic agent to bone Biodistribution studies of technetium-99m-labeled gem-bisphosphonate conjugate of methotrexate . J. Nucl. Med. 37:1996;105-107.
15. 211At- labelling of polymer particles for radiotherapy synthesis, purification and stability . J. Labelled Compd. Radiopharm. 33:1993;977-986.
16. 131I-labeled bisphosphonates with high in vivo stability and strong bone affinity. J. Nucl. Med. (in press).
17. 211At reaction. Appl. Radiat. Isot. 47:1996;135-143.
18. Lee Chung K., Aeppli D.M., Unger J., Boudreau R.J., Levitt S.H. Strontium-89 chloride (Metastron) for palliative treatment and bone metastases The University of Minnesota experience . Am. J. Clin. Oncol. 19:1996;102-107.
19. Lewington V.J. Cancer therapy using bone-seeking isotopes. Phys. Med. Biol. 41:1996;2027-2042.
20. Louw W.K.A., Dormehl I.C., van Rensburg A.J., Hugo N., Alberts A.S., Forsynth O.E., Beverly G., Sweetlove M.A., Marais J., Lotter M.G., van Aswegen A. Evaluation of samarium-153 and holmium-166-EDTMP in the normal baboon model. Nucl. Med. Biol. 23:1996;935-940.
21. Michael W.R., King W.R., Wakim J.M. Metabolism of disodium osteotropic ethane-1-hydroxy-1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey. Toxicol. Appl. Pharmacol. 21:1972;503-515.
22. 14C-clodronate (dichloromethylene bisphosphonate) disodium in mice. Toxicol. Appl. Pharmacol. 89, 287-292. Published erratum (1987) 91, 147.
23. 14C-clodronate (dichloromethylene bisphosphonate) disodium in mice. Toxicol. Appl. Pharmacol. 89, 287-292. Published erratum (1987) 91, 147.
24. Narula A.D., Zalutsky M.R. No-carrier-added astatination of N-succinimidyl-3-(tri-n-butylstannyl) benzoate (ATE) via electrophilic destannylation. Radiochim. Acta. 47:1989;131-135.
25. Nunn A.D., Loberg M.D., Conley R.A. Structure-distribution-relationship approach leading to the development of Tc-99m mebrofenin An improved cholescintigraphic agent . J. Nucl. Med. 24:1983;423-430.
26. Possinger K., Ziegler R. Bisphosphonates - Improved Treatment of Osteolysis in Malignant and Non-malignant Indications. 1996;Ciba Geigy Verlag. Wehr/Baden, Germany.
27. Vaidyanathan G., Zalutsky M.R. Protein radiohalogenation Observations on the design of N-succinimidyl ester acylation agents . Bioconjugate Chem. 1:1990;269-273.
28. Wingen F., Schmahl L. Pharmacokinetics of the osteotropic diphosphonate 3-amino-1-hydroxypropane-1,1-diphosphonic acid in mammals. Arzneimittel-forschung. 37:1987;1037-1042.
29. Zalutsky M.R., Narula A.S. A method for the radiohalogenation of protein resulting in decreased thyroid uptake of radioiodine. Appl. Radiat. Isot. 38:1987;1051-1055.
30. Zalutsky M.R., Narula A.S. Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate. Appl. Radiat. Isot. 39:1988;227-232.